Investors

We are a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and branded injectable and inhalation products.  We currently manufacture and sell over 20 branded and generic products in the U.S. and are developing a portfolio of over 20 commercial injectable and inhalation products that primarily target markets with high technical barriers to entry.

 

Press Releases

Oct 06, 2020
RANCHO CUCAMONGA, Calif. , Oct. 06, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) approved the Company’s Abbreviated New Drug Application (“ANDA”) for Atropine Sulfate injection 0.1mg/mL in the 10 mL Luer-Jet ®

Events & Presentations

More events are coming soon.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

 

Copyright ©2020 Amphastar Pharmaceuticals, Inc.

Privacy      Terms & Conditions

This site is intended for residents of the United States